FFAR2 and neoplasm: Although creating a pro‐inflammatory “hot” environment efficiently prompts anticancer therapy when the immunocompetence of patients is drastically reduced, inflammation is also a prerequisite for tumor progression.[41] Besides preventing tumor progression through anti‐inflammatory responses, SCFAs also boost antitumor immunity by interacting with FFAR2.